Morgan Stanley Reaffirms “Hold” Rating for Eli Lilly and Company (LLY)
A number of other brokerages have also commented on LLY. UBS AG lowered Eli Lilly and to a hold rating and set a $85.00 target price for the company. in a research note on Wednesday, July 26th. Jefferies Group LLC restated a buy rating and issued a $93.00 target price on shares of Eli Lilly and in a research note on Thursday, June 22nd. Sanford C. Bernstein restated an outperform rating and issued a $88.00 target price on shares of Eli Lilly and in a research note on Sunday, May 21st. Berenberg Bank restated a buy rating and issued a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Finally, Zacks Investment Research upgraded Eli Lilly and from a hold rating to a buy rating and set a $94.00 target price for the company in a research note on Monday, July 17th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $88.27.
Shares of Eli Lilly and (NYSE LLY) opened at 82.52 on Friday. The firm’s 50-day moving average is $80.87 and its 200 day moving average is $82.04. The company has a market cap of $87.06 billion, a price-to-earnings ratio of 35.71 and a beta of 0.34. Eli Lilly and has a 1-year low of $64.18 and a 1-year high of $86.72.
Eli Lilly and (NYSE:LLY) last issued its earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.86 earnings per share. Equities analysts expect that Eli Lilly and will post $4.16 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Morgan Stanley Reaffirms “Hold” Rating for Eli Lilly and Company (LLY)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/09/19/morgan-stanley-reaffirms-hold-rating-for-eli-lilly-and-company-lly.html.
In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the sale, the insider now directly owns 124,265,804 shares in the company, valued at $10,491,761,831.72. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 800,000 shares of company stock valued at $66,281,600. 0.20% of the stock is currently owned by corporate insiders.
Large investors have recently made changes to their positions in the company. Acrospire Investment Management LLC increased its stake in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at $128,000. San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and in the second quarter valued at $129,000. Heritage Trust Co acquired a new stake in shares of Eli Lilly and in the first quarter valued at $135,000. Finally, Point72 Asia Hong Kong Ltd increased its stake in shares of Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after buying an additional 1,239 shares in the last quarter. Institutional investors own 75.72% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.